If cannabis is reclassified to Schedule III, cannabis businesses won't be encumbered by onerous operating and taxing obstacles, federally-funded cannabis research will finally occur, and investment will soar, writes Steve Schain.

Alaska’s allowance of vending infused dairy butters, oils and fats clears the way for a broader array of infused-product offerings nationally and a more consumer-driven market.

Hemp-derived THC is readily available online and over-the-counter, and is cutting into legalized cannabis’ revenue despite growing state illegality, confusion over federal legality, and concerns regarding untested and unregulated products’ safety and potency.

Despite lessening criminal and administrative penalties and depository insurance obstacles, both the SAFE Banking Act and pending state cannabis banking legislation fail to put legal cannabis on an equal footing with other legitimate industries.

With cannabis-derived products outpacing the existing science and imposing massive health concerns, in October 2021 the FDA issued a “Cannabis-derived products data acceleration plan” to detect safety signals and accelerate research studies.